Eli Lilly Acquires Cancer Drug Maker Kelonia for Up to $7 Billion
The pharmaceutical giant bets on revolutionary in vivo CAR-T technology that reprograms patients' immune cells inside the body. The deal represents Lilly's largest acquisition in years.
Eli Lilly has agreed to acquire cancer drug developer Kelonia in a deal worth up to $7 billion, marking the pharmaceutical company's largest acquisition in recent years and its most significant bet on cutting-edge cancer immunotherapy. Kelonia specializes in developing revolutionary in vivo CAR-T technology that reprograms patients' T-cells inside the body to attack cancer cells, potentially eliminating the need for complex and expensive external cell processing procedures currently required for CAR-T treatments.
Traditional CAR-T therapy involves removing a patient's T-cells, genetically modifying them in a laboratory to recognize and attack specific cancer cells, and then infusing the engineered cells back into the patient. This process typically takes several weeks, costs hundreds of thousands of dollars, and requires specialized manufacturing facilities. Kelonia's approach aims to perform this genetic reprogramming directly inside the patient's body, potentially making the treatment faster, more accessible, and significantly less expensive.
The acquisition reflects Eli Lilly's strategic focus on expanding its oncology portfolio beyond its current diabetes and obesity drug franchises. Lilly has been actively seeking opportunities in innovative cancer treatments, particularly those involving immunotherapy approaches that harness the body's natural immune system to fight tumors. The company's leadership views CAR-T technology as one of the most promising areas in cancer treatment, with the potential to address multiple cancer types.
Kelonia's in vivo CAR-T platform represents a potentially transformative advancement in cancer immunotherapy. Current CAR-T treatments have shown remarkable success in treating certain blood cancers but have been limited by their complexity, cost, and manufacturing requirements. By developing a system that can reprogram immune cells directly inside the patient, Kelonia's technology could make CAR-T therapy available to a much broader patient population and potentially expand its use to solid tumors, which have proven more challenging to treat with existing approaches.
The $7 billion acquisition price reflects the high value that pharmaceutical companies place on promising cancer immunotherapy technologies. Eli Lilly's investment demonstrates confidence in Kelonia's scientific approach and development timeline, though the technology is still in relatively early stages of clinical testing. The deal is expected to close later this year, subject to regulatory approvals, and will significantly expand Lilly's research and development capabilities in the rapidly evolving field of cancer immunotherapy.
Originally reported by CNBC Markets.